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Nowadays, in the study of rheumatoid arthritis (RA), more and more interest is directed
towards an earlier effective therapeutic intervention and the determination of companion
markers for predicting response to therapy with the goal to prevent progressive joint
damage, deformities, and functional disability. With the present work, we aimed at
quantifying in a cohort of early RA (ERA) patients naïve to DMARD therapy, proteins
whose increase was previously found associated with RA: serum amyloid A (A-SAA) and
alarmins. Five A-SAA variants (SAA1a, SAA1b, SAA1g, SAA2a, and SAA2b) but also
S100A8 and S100A9 proteins were simultaneously quantified in plasma applying a
method based on single targeted bottom-up proteomics LC-MS/MS. First, we
compared their expression between ERA (n = 100) and healthy subjects (n = 100), then
we focused on their trend by monitoring ERA patients naïve to DMARD treatment, 1 year
after starting therapy. Only SAA1a and SAA2a levels were increased in ERA patients, and
SAA2a appears to mostly mediate the pathological role of A-SAA. Levels of these variants,
together with SAA1b, only decreased under biologic DMARD treatment but not under
methotrexate monotherapy. This study highlights the importance to better understand the
modulation of expression of these variants in ERA in order to subsequently better
characterize their biological function. On the other hand, alarmin expression increased
in ERA compared to controls but remained elevated after 12 months of methotrexate or
biologic treatment. The work overcomes the concept of considering these proteins as
biomarkers for diagnosis, demonstrating that SAA1a, SAA1b, and SAA2a variants but
also S100A8 and S100A9 do not respond to all early treatment in ERA and should be
rather considered as companion markers useful to improve the follow-up of treatment
response and remission state. Moreover, it suggests that earlier use of biologics in
addition to methotrexate may be worth considering.
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Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic inflammation of synovial joints. In
case of severe outcome, the disease results in joint destruction
and permanent disability (1–3). Even if many advances have
been made in the understanding of RA immunopathology, its
etiology still remains not fully elucidated and the prognosis is
highly variable. An early recognition of RA can ensure a swift
start of the appropriate drug therapy (4, 5). It has been proposed
that, ideally, RA diagnosis should be made in the first 12 weeks of
manifestation (6). This would result in a better health outcome of
patients, promoting higher chance to achieve remission and
preserve joint functionality in regard to a longer delay in
assessment (6). Therefore, in the last years, the study of RA
has moved towards the early phases of the disease.
Moreover, in the ordinary clinical practice, RA patient
assessment is based on the disease activity score (DAS28).
Despite its widespread use, the main limitation of this scoring
system is the inaccuracy in detecting joint inflammation in
patients considered as in remission but who may still have
joints destruction (7–9). So, the definition of potential
companion biomarkers associated to prognosis and therapeutic
response could be useful in better characterizing RA disease
activity. Among them, the over-expression of two classes of
proteins has been extensively associated with RA: serum
amyloid A (SAA) and S100 proteins (S100A8, S100A9) (10).
For the time being, A-SAA and alarmins have often been
considered for diagnostic purpose, but they seem to be quite
generic inflammatory markers. Indeed, we want to move forward
by rather examining A-SAA variants and S100 proteins in
monitoring RA activity and predicting effectiveness of a given
therapy in the first year of treatment.
SAA is an acute-phase protein mainly released by
hepatocytes, and its concentration rises in trauma, cancer,
infection, and inflammatory disease such as RA (11–15). SAA
has also been suggested as an indicator of RA activity,
considering its correlation with the disease activity score (15–18).
However, less is known about the different role of SAA
variants in RA. In humans, there are four different genes
encoding SAA: SAA1, SAA2, SAA3, and SAA4. SAA3 was
initially referred to as a pseudogene but then its expression was
demonstrated in mammary epithelial cell (19), while SAA4 is
constitutively expressed. The so-called acute-phase SAA proteins
(A-SAA) are encoded by SAA1 and SAA2 genes, which are
induced during acute-phase response. The functional role of
A-SAA is now debating considering the growing criticism
towards studies using recombinant human SAA (rhSAA), a
hybrid form of SAA1 and SAA2, contaminated with bacterial
lipopolysaccharides and lipoproteins and therefore enhancing
TLR2 and TLR4 pathways (20, 21). It highlights the
inconsistency among endogenous A-SAA and rhSAA activity
(22, 23), as well as the importance of redefining pro-
inflammatory properties of A-SAA. Recently, researchers
discovered that SAA1 and SAA2 promote differentiation of
pathogenic Th17 cells (24) using loss- and gain-of-function
mouse models and that SAA1 initiates type 2 immunity takingFrontiers in Immunology | www.frontiersin.org 2part to inflammatory disease (25). It has also been shown that
rhSAA1, free of any bacterial contaminants, lacked the
previously reported TLR2-mediated activities but preserved its
role in neutrophil chemotaxis in synergy with CXCL8 via
FPR2 (26).
Another issue in the study of A-SAA is the simultaneous
presence of different isoforms Kim et al. showed in lung cancer
differences in the expression of each subtype (27). Indeed, SAA1
and SAA2 are polymorphic with three and two variants,
respectively: SAA1a, SAA1b, SAA1g, SAA2a, and SAA2b. The
difficulty in the identification of these different variants consists
in their high homology (>90%). Since they only differ in few
amino acids, commercial antibodies usually react with all
isoforms. Recently, we developed a method to quantify
simultaneously each of these variants by single targeted
bottom-up proteomics LC-MS/MS (28). The expression of
these different isoforms was investigated in various immune-
mediated inflammatory diseases (IMIDs: RA, ankylosing
spondylitis, systemic lupus erythematous, systemic sclerosis,
osteoarthritis) highlighting quantitative as well as qualitative
differences among A-SAA variants. Moreover, a negative
correlation was determined between SAA1a and SAA1b levels,
and a mirror symmetry was observed between both levels
throughout all IMIDs (28). In addition to A-SAA variants, our
method quantified also S100A8 and S100A9 proteins. S100A8
and S100A9 alarmins also known as myeloid-related protein
(MRP)-8 and MRP-14, or calgranulin A and B, respectively, are
two members of the S100 protein family which are expressed in
monocytes, granulocytes, and neutrophils to modulate
inflammatory response (29). The extracellular heterodimer
they formed is called calprotectin, and it is routinely measured
in gastrointestinal inflammation (30, 31). However, high levels of
S100A8 and A9 have also been detected in many immune system
dysfunction diseases such as psoriatic arthritis, systemic lupus
erythematosus, ankylosing spondylitis, and RA (28, 32–34). In
RA, neutrophils are strong producers of the S100A8/A9 alarmins
whose presence is linked to joint erosion via the induction of
inflammation (35–37).
The aim of the present study was to characterize the
expression of the five different A-SAA variants (SAA1a,
SAA1b, SAA1g, SAA2a, and SAA2b) and S100A8/A9 proteins
in a large national cohort of early RA (ERA) patients, in regard to
healthy control subjects. Proteins levels were quantified
employing the method we previously developed by LC-MS/MS
(28). Treatment-naïve patients were recruited after their first
medical examination and subsequently after 12 months of
treatment in order to investigate the therapeutic effect on A-
SAA and S100 protein expression.MATERIAL AND METHODS
Patients
One hundred patients (80 females, 20 males) suffering from ERA
(mean age 34.5 ± 9.9; M ± SD) and 100 healthy controls, well
matched for age (34.4 ± 8.9) and sex (80 females, 20 males), wereAugust 2021 | Volume 12 | Article 638814
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disease classification criteria (38). The cohort of ERA included
patients younger than 50 years old, with a disease duration <3
months and naïve to DMARD therapy at time 0 (T0). Each
patient was assessed for DAS28 using C-reactive protein
(DAS28-CRP), clinical disease activity index (CDAI), and
simplified disease activity index (SDAI) at baseline and during
a 1-year follow-up. The response to therapy takes into account
the modification of DAS28-CRP after treatment so that it can
be evaluated as good, moderate, or absent according to the
EULAR response criteria (39). In our study, ERA patients were
sorted in good responders (R; n = 48) and non-responders (NR;
n = 48). The response was considered good when the DAS28-
CRP at T12 was <3.2 and decreased by a factor of at least 1.2
from baseline (T0) (39). All the other patients belonged to NR.
Four patients were removed from the analysis because they did
not fulfill the criteria for either R or NR. Human blood samples
were further collected from patients after 1 year of treatment
(T12), in order to evaluate the response to treatment. Table 1
summarizes the clinical data of participants who were included
in the study.
Ethics
An informed consent was obtained from all recruited subjects
and the study was approved by Ethics Committee of the
Cliniques Universitaires Saint-Luc (Bruxelles; Study
No. B403201317717).Frontiers in Immunology | www.frontiersin.org 3Sample Collection
Human blood samples were collected in standard conditions and
allowed to coagulate in plain glass tubes or EDTA-treated tubes
to isolate serum or plasma, respectively. Serum and plasma were
obtained after centrifugation at 2000 xg for 10 min, room
temperature. Supernatants were aliquoted and stored at −80°C
until use.
Quantitation of A-SAA Variants and
S100 Proteins
To quantify simultaneously in plasma the five different A-SAA
variants, S100A8 and S100A9 proteins, we applied a method that
has been recently developed in our laboratory (28): targeted
bottom-up proteomics LC-MS/MS. Briefly, internal standard
(ISTD) as well as all standard peptides and proteins for S100
and SAA were dissolved in H2O/ACN/FA (90:10:0.1, v/v),
aliquoted, and stored at −80°C until use. A mix of calibrant
solution and bovine plasma was loaded on a 96 plate in duplicate;
concurrently, the samples were mixed with H2O/ACN/FA
(80:20:0.1, v/v). Then, ammonium bicarbonate solution
containing 33.3% of MeOH and ISTD was added in each well.
Finally, after 10 min of incubation at 100°C, trypsin solution was
added overnight at 37°C. Ammonia was added to quench the
reaction. The Oasis Max SPE plate of 10 mg (Waters
Corporation, Dublin, Ireland) has been used for extraction. For
LC-MS analysis, ultra-high-pressure liquid chromatography




Age - Mean (range) 34.4 (19–51) 34.5 (16–50)
RF+ % – 64






Clinical measures Mean (range) T0 Mean (range) T12
DAS28-CRP – 4.4 (1.21–7.27) 2.8 (1.21–5.9)
CRP mg/dl – 2.2 (0.09–26) 0.5 (0.02–10)
SDAI – 23.6 (0–70) 10 (0.1–77)
CDAI – 21.5 (0–65) 8.7 (0–55)
TJC – 9.4 (0–33) 3.5 (0–45)
TJC 28 – 7 (0–26) 2.5 (0–23)
SJC – 6.4 (0–27) 1.6 (0–19)
SJC 28 – 4.9 (0–26) 1.3 (0–19)
HAQ – 1 (0–2.8) 0.7 (0–3.8)
VAS medical – 42.4 (5–89) 16 (0–70)
VAS patient – 54.1 (0–100) 33.4 (0–90)
VAS pain – 54.4 (0–100) 32 (0–90)
VAS fatigue – 55.5 (0–100) 42.5 (0–96)August 2021 | VolumeRF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; DAS28–CRP, Disease Activity Score 28 joints; CRP, C-reactive protein; SDAI, Simplified Disease Activity Index; CDAI,
Clinical Disease Activity Index; TJC 28: 28-Tender Joint Count; SJC 28, 28-Swollen Joint Count; HAQ, Health Assessment Questionnaire; VAS, Visual Analogue Scale.
*15% anti-IL-6; 15% anti-JAK1/JAK2; 70% anti-TNFa.
Clinical parameters of 100 ERA patients enrolled in the study at time 0 (T0) and after 12 months of treatment (T12) and compared to 100 healthy volunteers (HV). ERA, early rheumatoid arthritis.12 | Article 638814
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column (Phenomenex, Torrance, CA, USA). The separation
was performed by gradient mode. MS/MS detection was
achieved on a 6495 LC-MS TripleQuadrupole supplied with
the iFunnel Technology (Agilent Technologies) and operated
using positive electrospray ionization.
ELISA
The concentration of total A-SAA and calprotectin was detected
in serum by commercial ELISA kits (A-SAA from Thermo Fisher
Scientific, Waltham, MA, USA; calprotectin from Bühlmann,
Schönenbuch, Switzerland) used according to the manufacturer’s
instructions. The calibration range was from 9.4 to 600 ng/ml
and 4 to 240 ng/ml for A-SAA and calprotectin, respectively.
Serum was diluted 1:1000 for A-SAA and 1:100 for calprotectin.
All experiments were performed in duplicate.
Statistics
Statistical analysis was performed with SPSS (SPSS/PC Statistical
Package for the Social Science, update for 10.1. Chicago, IL: SPSS
Inc., 2000), Graph Pad Prism 6 software, and G*Power 3.1 software.
Comparisons
Concentrations (ng/ml) obtained from LC-MS/MS and ELISA
are presented after a logarithmic transformation (base 10), and to
determine whether data were normally distributed, a
D’Agostino-Pearson test was applied. Comparisons between
groups were performed using non-parametric tests. Analysis of
control vs. T0 or T12 was made with the Kolmogorov–Smirnov
test for unpaired data, andWilcoxon signed rank test was applied
for paired data between T0 and T12. Differences were considered
as statistically significant when p-value was ≤0.05.
Power Analysis
We performed a post hoc power analysis to determine if the
sample size was appropriate. The power analysis was based on
the measure of the effect size, through Cohen coefficient
calculation (40), and was performed for all statistically
significant comparisons. We considered that the sample size
was correct when it allowed to reach a level of power ≥ 0.95.
Correlation
To evaluate the statistical correlation among proteins and clinical
measures, Spearman’s rank correlation coefficient was calculated.
ROC Curves
Receiver operating characteristic (ROC) curves were plotted to
determine marker performance in discriminating ERA patients
from controls. It was also estimated whether a combination of
different proteins might increase this performance. Hence, a
logistic regression was applied to calculate the weight given by
each marker and to determine the formula for having a
combined risk index. In order to evaluate whether the marker
combination might increase the performance in distinguishing
ERA from healthy subjects, area under curve (AUC) was
calculated with 95% confidence interval, evaluating sensitivity
and specificity of each marker and their combination.Frontiers in Immunology | www.frontiersin.org 4RESULTS
Classification of Patients
In our cohort, we had 48 R and 48 NR. Patients of the R group
had a mean DAS28-CRP value of 4.6 at T0 decreasing to 2 at T12.
In the NR group, the mean DAS28-CRP value was of 4.4 at T0
and 3.6 at T12 (Figure 1). The main treatment was methotrexate
(88%) followed by biologics (23%), corticosteroids (11%), and
hydroxychloroquine (5%).
Quantification of A-SAA
The expression of five A-SAA variants was quantified in plasma
of 100 ERA patients and 100 healthy controls by LC-MS/MS.
Comparisons were considered as statistically significant when
p-value was ≤0.05 and power of sample size was ≥0.95.
In ERA patients at T0 compared to healthy subjects, we found
that the concentration of SAA1a and SAA2a variants was
significantly increased with a p-value of 0.02 and <0.001,
respectively (Figure 2A). When comparing T0 vs. T12, a
significant decrease was observed after therapy for SAA1a
(p-value = 0.02) and SAA2a (p-value = 0.003), suggesting that
these two variants are good responders to treatment (Figure 2A).
Subsequently, we examined the variation in the R and NR groups
(Figure 2B) for all A-SAA variants. It is interesting to observe
that the significant difference was only present in the group of
good responders. Indeed, when comparing ERA patients at T0 vs.
controls, we observed a significant increase for SAA1a
(p-values = 0.005) and SAA2a (p-value < 0.001) only in the R
group (Figure 2B). Similarly, the decrease at T12 compared to
T0 was also only significant in the R group for SAA1a and
SAA2a with p-values of 0.01 and <0.001, respectively.FIGURE 1 | Classification of ERA patients in good and non-responders
according to DAS28-CRP. The 100 patients suffering from ERA were divided
in two groups: good (R) and non-responders (NR) according to the variation
of DAS28-CRP from T0 and T12 (after 12 months of treatment). When
DAS28-CRP ≤ 2.6, the patient is in remission (dotted red line). The mean for
each group is indicated with a full red line. Four patients were removed from
the analysis because they did not fulfill the criteria for either R or NR.August 2021 | Volume 12 | Article 638814
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variant, we observed that the contribution of SAA1a and
SAA1b was higher compared to the others, and in ERA
patients, the proportion of SAA1b and SAA2a showed a
tendency to decrease and increase, respectively, compared to
controls (Supplementary Figure S1).
Finally, we quantified by ELISA the expression of total A-SAA
(Figures 2A, B) and also observed in the R group a significant
increase of A-SAA for ERA patients at T0 vs. controls (p-value <Frontiers in Immunology | www.frontiersin.org 50.001) and a decrease at T12 vs. T0 (p-value < 0.001). We also
found a significant correlation among ELISA results and the
expression of SAA1a, SAA1b, and SAA2a (Table 2).
Quantification of Alarmins
Simultaneously to A-SAA variants, the LC-MS/MSmethod allowed
to quantify S100A8 and S100A9 proteins. As expected, their
expression was significantly increased in plasma of ERA patients
(T0) vs. healthy subjects with a p-value < 0.0001 (Figure 3A).A
B
FIGURE 2 | Quantification of A-SAA by LC-MS/MS and ELISA. (A) Expression of A-SAA variants and total A-SAA in healthy volunteers (controls, CTRL) and ERA
patients at time T0 and after 12 months of treatment (T12). (B) Expression of A-SAA variants and total A-SAA in ERA patients sorted in two groups: good (R) and
non-responders (NR). Scatter dot plots represent the median with interquartile range. *p-value ≤ 0.05, **p-value ≤ 0.01, ***p-value ≤ 0.001 (Kolmogorov–Smirnov
test); #p-value ≤ 0.05, ##p-value ≤ 0.01; ###p-value ≤ 0.001 (Wilcoxon test).August 2021 | Volume 12 | Article 638814
Ciregia et al. Early Rheumatoid Arthritis: Companion MarkersIn contrast to A-SAA, we did not observe any significant
decrease at T12, after treatment. Indeed, the intensity of
S100A8 and S100A9 was still significantly increased compared
to controls with a p-value of 0.004 and <0.0001, respectively, and
with no variation between T0 and T12. That remained
unchanged when patients were reclassified in the R and NR
groups. There was no difference between R and NR at T0, or
either at T12. The level of both proteins still remained
significantly higher for ERA patients vs. healthy subjects, at T0
and T12, for R and NR classes (Figure 3B). Thereafter, the
presence of calprotectin in serum was quantified. Figure 3A
shows that the expression of calprotectin in ERA was increased
compared to controls (p-value = 0.0011). While calprotectin at
T0 compared with controls increased in the R and NR classes
(with a p-value of 0.04 and 0.0011, respectively), no difference
was observed between R and NR at T0, or either at
T12 (Figure 3B).Frontiers in Immunology | www.frontiersin.org 6Clinical Correlations
Correlation parameters among protein intensities and clinical
features were determined. Results are summarized in Table 2.
A-SAA Variants
Only total A-SAA, SAA1a, and SAA2a showed a significant
positive correlation with DAS28-CRP, which is in accordance with
differences observed between the R and NR groups as described
above for A-SAA variants. It is worth to mention that SAA1a and
SAA2a variants were statistically more correlated with functional
parameters in regard to total A-SAA. SAA1a was correlated with
SDAI, SJC, and VAS medical, whereas SAA2a, besides these, also
correlated with HAQ, VAS patient, and VAS pain (Table 2).
Alarmins
The expressions of S100A8 and S100A9 were strictly correlated
between themselves but not to other clinical parameters.TABLE 2 | Statistical correlation among proteins and clinical measures.
1a 1b 1g 2a 2b A-SAA S100A8 S100A9 CALP
1a a – -0.28 n.s. 0.581 n.s. 0.296 0.274 0.376 n.s.
b 0.005 3e-10 0.005 0.006 1e-04
1b a -0.28 - 0.212 0.200 0.252 0.480 n.s. n.s. 0.244
b 0.005 0.036 0.049 0.012 2e-06 0.022
1g a n.s. 0.212 – n.s. 0.213 n.s. 0.250 n.s. n.s.
b 0.036 0.034 0.012
2a a 0.581 0.200 n.s. - n.s. 0.655 0.393 0.517 0.393
b 3e-10 0.049 2e-12 5e-05 3e-08 1e-04
2b a n.s. 0.252 0.213 n.s. – n.s. n.s. 0.250 n.s.
b 0.012 0.034 0.012
S100A8 a 0.274 n.s. 0.250 0.393 n.s. 0.276 - 0.681 0.433
b 0.006 0.012 5e-05 0.008 7e-15 2e-05
S100A9 a 0.376 n.s. n.s. 0.517 0.250 0.427 0.681 – 0.434
b 1e-04 3e-08 0.012 3e-05 7e-15 2e-05
DAS28 a 0.239 n.s. n.s. 0.300 n.s. 0.208 n.s. n.s. 0.309
b 0.017 0.002 0.049 0.003
SDAI a 0.225 n.s. n.s. 0.238 n.s. n.s. n.s. n.s. 0.251
b 0.025 0.017 0.017
CDAI a n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
b
TJC a n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
b
TJC28 a n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
b
SJC a 0.264 n.s. n.s. 0.226 n.s. n.s. n.s. n.s. n.s.
b 0.009 0.025
SJC28 a n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
b
CRP mg/dl a 0.293 n.s. n.s. 0.415 n.s. 0.450 n.s. 0.263 0.292
b 0.003 2e-05 8e-06 0.008 0.005
HAQ a n.s. n.s. n.s. 0.250 n.s. n.s. n.s. n.s. n.s.
b 0.012
VAS medical a 0.250 n.s. n.s. 0.240 n.s. n.s. n.s. n.s. n.s.
b 0.013 0.016
VAS patient a n.s. n.s. n.s. 0.238 n.s. n.s. n.s. n.s. 0.343
b 0.017 0.001
VAS pain a n.s. n.s. n.s. 0.207 0.227 n.s. n.s. n.s. 0.220
b 0.041 0.025 0.039
VAS fatigue a n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.241
b 0.029August 2021 | Volume 12 | Article 6a, correlation coefficient; b, p-value; n.s., not significant.
The clinical correlations among A-SAA variants and S100 proteins with clinical features (at time T0) were determined by calculating the Spearman’s rank correlation coefficient.38814
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CRP, which is coherent with the absence of variation observed
for these proteins in response to treatment. Interestingly, when
the correlation between S100A8 and S100A9 was evaluated, a
better correlation of their expression was observed in ERA (T0)
compared to healthy subjects (Supplementary Figure S2A).
Same result was obtained when calprotectin was correlated
with S100A8 and S100A9: correlation was only observed with
ERA patients but not with controls (Supplementary Figures
S2B, C). Moreover, if calprotectin is correlated with SDAI and
VAS (patient, pain, fatigue), the single alarmins did not show any
correlation with clinical parameters (Table 2).
ROC Curves
In order to define the clinical potential of selected proteins to
differentiate between ERA patients and healthy controls, ROC
curves were calculated with A-SAA variants, alarmins, and C-
reactive protein (CRP) intensities. In addition, a logistic
regression analysis was applied to assess the area under the
curve (AUC) of the ROC curves obtained with combined
markers, in order to analyze whether the discriminative power
might increase. The combinations giving the better ROC curves
are presented in Supplementary Figure S3.Frontiers in Immunology | www.frontiersin.org 7A-SAA Variants
ROC curves were calculated for the five A-SAA variants, but
single variant analysis did not provide any significant interest for
clinical diagnosis (Supplementary Figure S4A). We highlighted
that the best curve was obtained with SAA2a variant, which was
similar to the one obtained with total A-SAA. Nevertheless, it
remains interesting to mention that the best ROC curve was
derived from the SAA2a/CRP combination (Supplementary
Figures S3A, C), while ROC curves including total A-SAA had
slightly less diagnostic power (Supplementary Figures S4B, C).
Alarmins
ROC curves with alarmins were calculated, alone or in
combination with other parameters. The best ROC curve was
achieved with the combination S100A8/S100A9/CRP
(Supplementary Figure S3B), which outreached the
discriminating power of each single protein (Supplementary
Figure S3C).
Expression of Proteins in Response
to Treatment
The influence of different DMARDs prescribed for therapy was
explored by examining the expression of A-SAA variants andA
B
FIGURE 3 | Quantification of proteins S100A8, S100A9, and calprotectin. (A) Expression of alarmins in controls (CTRL) and ERA patients at time T0 and after 12
months of treatment (T12). (B) Variation of the expression of alarmins in good (R) and non-responders (NR). Scatter dot plots represent the median with interquartile
range. *p-value ≤ 0.05, **p-value ≤ 0.01, ***p-value ≤ 0.001 (Kolmogorov–Smirnov test).August 2021 | Volume 12 | Article 638814
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patients treated with methotrexate monotherapy (n = 58 with
24% NR) were separated from patients treated with biological
drugs (n = 23 with 13% NR). CRP levels decreased at T12 with
both treatments compared to baseline, with a higher effect under
biologic therapy (Supplementary Figure S5A).
A-SAA Variants
In the comparison T0 vs. T12, there was a significant decrease at
T12 for SAA1a, 1b, and 2a with a p-value of 0.0011, 0.03, and
<0.0001, respectively, only under biologic antirheumatic. When
ERA patients were sorted in R and NR groups, the significantFrontiers in Immunology | www.frontiersin.org 8decrease at T12 vs. T0 was only observed in the R group with a
p-value of 0.002, 0.002, and <0.0001 for SAA1a, 1b, and 2a,
respectively (Figure 4A). Total A-SAA levels decreased only
under biologic therapy (p-value < 0.001) (Supplementary Figure
S5B). By sorting R and NR patients, the decrease emerged also in
the methotrexate group but only for good responders, and it was
more pronounced under biologic therapy (Supplementary
Figure S5B).
Alarmins
For alarmins, we did not observe any significant reduction at T12
when patients received methotrexate. A difference was foundA
B
FIGURE 4 | Differences in the expression of proteins according to the treatment. Graphs depict the expression of A-SAA variants (A) and alarmins (B) in patients, at
T0 and T12, sorted by treatment: methotrexate monotherapy (MTX) or biologics (BIO). Scatter dot plots represent the median with interquartile range.
*p-value ≤ 0.05, **p-value ≤ 0.01, ***p-value ≤ 0.001 (Wilcoxon test). R, good responders; NR, non-responders.August 2021 | Volume 12 | Article 638814
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responders (p-value = 0.01) (Figure 4B). However, it is
important to point out that the NR group under biologic
therapy was too small (n = 3) for a consistent statistical analysis.DISCUSSION
In our cohort of 100 ERA patients, of which 88% had
methotrexate and 23% received biologics, we only observed the
presence of 48 good responders despite 1 year of treatment.
Further, in the group of good responders, we still observed the
expression of inflammatory markers.
The early therapeutic intervention is crucial in ERA, leading
to better long-term prognosis and prevention of structural
damage. At this time, antibodies against cyclic citrullinated
proteins and rheumatoid factor are used to diagnose ERA in
common clinical practice (41). On the other hand, the parameter
commonly used to evaluate the disease activity of RA is DAS28-
CRP, a composite score based on clinical and laboratory data,
specifically CRP. Nevertheless, some limitations in its use have
emerged (7–9, 42, 43), so companion markers take up a key role
in improving the predictability of patient’s response giving a tool
for helping treatment’s choice. Some proteins have been
introduced (41) to gradually unveil RA pathophysiological
mechanisms and response to treatment such as A-SAA and
alarmins. These are typical inflammation biomarkers whose
increase has been widely reported in RA. However, in this
study, we explored the expression level of A-SAA variants in
ERA, which has been less described, and of alarmins that have
been mainly studied as the heterodimeric calprotectin in serum,
but not as monomeric proteins in plasma as recommended by
Nordal et al. (44) Above all, we focused on their trend to decrease
from baseline in DMARDs-naïve patients after 1 year of
treatment, exploring their usefulness as companion markers
for monitoring RA activity and the inflammatory process. This
cross-sectional and longitudinal study belongs to the early phase
of markers validation. Other studies will be necessary to assess
their analytical and clinical validation.
A-SAA is progressively being considered as a more reliable
factor than CRP in detecting subclinical inflammation. Indeed,
A-SAA was shown to have a better association with the disease
activity than CRP in inflammatory rheumatic diseases (16, 18,
43, 45, 46). Interestingly, the well-described biological roles of A-
SAA have been recently reconsidered. Actually, several studies
have now demonstrated the unreliability of using bacterial
recombinant form of A-SAA due to (i) its hybrid amino acid
composition between SAA1 and SAA2 isoforms and (ii) the
presence of bacterial contaminants enhancing pro-inflammatory
pathways (18, 21–23, 26). They also substantiated the need of
differentiating A-SAA variants from each other, which cannot be
performed by an antibody-based approach such as the
ELISA kits.
The quantification of the five different A-SAA variants is
challenging since they differ in few amino acids (Supplementary
Data 1). Lately, we have developed a method by LC-MS/MS which
allowed to simultaneously discriminate the five different A-SAAFrontiers in Immunology | www.frontiersin.org 9variants (28). This earlier work found a difference in the
expression of isoforms related to RA disease activity. Moreover,
a negative correlation was observed between SAA1a and SAA1b
levels. Hence, this gave us a hint about the clinical relevance of
distinguishing these variants in different immune-mediated
inflammatory diseases. Therefore, we have now measured
A-SAA variants in plasma from ERA patients and healthy
controls. Besides LC-MS/MS, total A-SAA was quantified in
serum by ELISA. We observed the increase of A-SAA in ERA
patients at T0 compared to controls and a new significant decrease
after 12 months of therapy for the good responders. This trend
was observed by MS for SAA1a and SAA2a expression, the latter
isoform presenting the most statistically significant variation.
Furthermore, we observed that total A-SAA was correlated with
SAA1a, SAA1b, and mainly with SAA2a. These data suggest that
the effect of A-SAA could be primarily related to SAA2a. Actually,
when ROC curves were plotted for assessing the clinical potential
of A-SAA variants, the best curve included SAA2a but not total
A-SAA. It does not mean that SAA2a should be considered as a
useful biomarker; we can rather state the weak usefulness of A-
SAA proteins as biomarkers compared to CRP, but it suggests that
it is important to differentiate A-SAA variants when studying the
role of A-SAA in chronic inflammatory diseases. Accordingly, it
should be highlighted that only SAA1a and SAA2a were
correlated with the DAS28 as also observed with A-SAA. But
most importantly, unlike total A-SAA, only SAA1a and
specifically SAA2a were correlated with several clinical
parameters (i.e., SDAI, SJC, HAQ, and VAS). Among these
correlations, the one with the SJC parameter is noteworthy as it
is directly related to a joint alteration and patients considered as in
remission could experience joint damage. So, these observations
suggest that not all variants have the same weight in ERA
pathophysiology and that single variants can also give more
information than total A-SAA.
Then, we examined whether there was a difference in the
expression of A-SAA in relation to the type of therapy used at
T12. One-year treatments were diversified; nevertheless, we
identified two groups of treated ERA patients at T12: a first
group receiving methotrexate as monotherapy, and a second
group receiving biologic antirheumatic drugs. The group of
patients under methotrexate showed a higher percentage of NR
than the group using biologic drugs.
As already described (16), ERA patients treated with biologic
therapy showed at T12 a higher decrease in A-SAA levels
compared to those treated with methotrexate monotherapy.
Some authors also assessed that the concentration of A-SAA
decreased at the beginning of therapy but that it was followed by
a slight A-SAA increase after 12 months of treatment (47).
Interestingly, when we focused on the single variants, we
observed that the response to treatment was only observed for
SAA1a, SAA1b, and SAA2a in good responders under biologic
therapy but not after methotrexate monotherapy, unlike CRP
and total A-SAA. This suggests that single variants could be
more useful to stratify RA patients and to monitor treatment.
The alarmins S100A8 and S100A9 and their corresponding
heterodimer, calprotectin, are proteins involved in the
inflammatory process in RA (32, 33, 48). Consistent withAugust 2021 | Volume 12 | Article 638814
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proteins in ERA patients compared to healthy subjects. We also
calculated a good ROC curve by combining S100A8/S100A9/
CRP, but our study did not include any disease control group, so
the observed specificity was not highly relevant. After all,
alarmins and A-SAA proteins are well-known ubiquitous
markers of inflammation, and cannot replace gold standards in
RA diagnosis such as antibodies against cyclic citrullinated
proteins and rheumatoid factor. In fact, the substantial
observation of our longitudinal study was that alarmin levels
remained elevated after 1 year of treatment. There was even no
difference between good and non-responders, and also no
correlation of S100A8 and S100A9 with DAS28-CRP.
Moreover, we also observed that the expression of S100A8 was
even more correlated with S100A9 under pathological conditions
compared to healthy subjects. The same observation was pointed
out when correlating calprotectin with S100A8 and S100A9. This
might suggest a different role of S100 for ERA patients compared
to controls.
The usefulness of alarmins as companion markers for
treatment response has been extensively debated, with various
results. This is linked to the wide differences in cohorts and
selected therapies for different studies (49–56). In our study, we
observed that the group under methotrexate or biologic DMARD
treatment did not present any decrease of alarmin expression,
except for a small decrease of calprotectin at T12 in the R group
receiving biologic drugs. This is in accordance with another
study suggesting that calprotectin could not be considered as a
predictor of clinical response to methotrexate in ERA (49, 56).
Conversely, it has also been proposed that calprotectin can
decrease during therapy with biologics agents (50, 51).
Hence, in line with previous observations (47), the outcome
of our longitudinal analysis suggests that despite the fact that
clinical evaluation classifies a patient as being in remission
according to the DAS28-CRP, some inflammatory markers can
still remain and the assessment of classical markers might not be
sufficient to properly follow the inflammatory process. Indeed,
CRP is widely used as indicator of chronic inflammation, also in
RA, but it has already been suggested (43) that CRP by itself
cannot be used to evaluate the remission status in RA patients.
Likely, the systemic inflammation process is not coupled to the
radiological evidence of persisting injury (43). Thus, patients can
be considered in clinical remission but still having joint
inflammation, which could be highlighted by the presence of
calprotectin (or S100A8/S100A9 proteins). Actually,
calprotectin, unlike CRP, is a protein that during inflammation
is mainly produced by macrophages and granulocytes infiltrating
the RA synovial membrane (51). Moreover, the presence of
S100A8/A9 alarmins is linked to joint erosion in RA (35–37).
Therefore, it directly reflects synovial inflammation (52, 55, 56).
In conclusion, in RA treatment, the achievement of clinical
remission has the ultimate goal to prevent progressive joint
damage, deformities, and functional disability. Anyway,
structural destruction can occur independently of arthritis
activity assessed by DAS28 (7, 9, 57). In order to overcome
this limit, our study highlighted the importance to
simultaneously quantify A-SAA variants and alarmins. Indeed,Frontiers in Immunology | www.frontiersin.org 10SAA1a, SAA1b, and SAA2a followed the response to therapy
after 1 year of biologic DMARD treatment but not under
methotrexate, and SAA2a was the variant which appeared to
mostly mediate the role of A-SAA. Currently, there are few
papers describing these variants whose study is challenging. Our
work highlighted the need of differentiating isoforms of A-SAA
in the study of RA. Indeed, it will be interesting to characterize
their biological role, since some variants are modulated in
inflammatory condition and after response to treatment, while
some others are not. Therefore, this fundamental and
translational research paves the way for future functional
studies. Currently, there are no papers describing these
variants and their biological role, mainly because of the
absence of reliable commercial SAA proteins/variants for in
vitro/in vivo tests. Hence, in our laboratory, we have planned
to investigate the functional role of the variants by creating an in
vitro model of cells secreting each variant. By transduction, we
have already obtained stable cell lines, each expressing a different
A-SAA variant, that could be used to stimulate primary human
fibroblast-like synoviocytes (data not shown).
On the other hand, the increase of S100A8/S100A9
expression was detected in ERA but there was no decrease
after 1-year treatment. Therefore, we proposed that, even
though patients can be considered in remission according to
the DAS28-CRP, some inflammatory markers can still remain. In
this perspective, it is important to stress that we want to go
beyond the concept of considering these proteins as biomarkers.
Indeed, a larger cohort of patients would have been necessary for
a clinical study with a diagnostic purpose. We rather suggest in
this preclinical study SAA2a, S100A8, and S100A9 as potential
companion markers that should be validated on new cohorts.
These could be used for a better follow-up of the disease state
fostering higher chance to achieve remission and preserve joint
functionality in regard to a longer delay in assessment.
We acknowledged some limitations to our work. Firstly, the
studied ERA population reflects a real-life clinical setting, and
thus has non-standardized treatment protocol: this has led to a
reduction in the sample size for subgroup analysis. Even if the
aim of the work was not to find diagnostic biomarkers, we should
foresee to select a cohort of patients adhering to a predefined
treatment protocol in order to achieve wider consistent statistical
analysis, and to monitor quantitative differences for these
companion markers at different times. Moreover, it should be
interesting to dose these proteins with a shorter and longer
timing in order to define more precisely a cut-off of value that
could suggest a relapse of the disease and/or the presence of
subclinical inflammation.
On the other hand, the study has the strength of using ERA
cohort naïve to therapy proposing companion markers which
could overcome the limits of DAS28-CRP in detecting
subclinical inflammation. In addition, our observations
indicate that the assessment of these companion markers can
help to better appraise RA activity and identify patients needing a
more intensive biologic therapy, before the appearance of
structural damage. Probably, the common use of methotrexate
as first choice treatment may be rather accompanied by a
prompter use of biologic drugs.August 2021 | Volume 12 | Article 638814
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et al. Calprotectin (a Major S100 Leucocyte Protein) Predicts 10-Year
Radiographic Progression in Patients With Rheumatoid Arthritis. Ann
Rheumatol Dis (2010) 69:150–4. doi: 10.1136/ard.2008.103739
38. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd,
et al. 2010 Rheumatoid Arthritis Classification Criteria: An American
College of Rheumatology/European League Against Rheumatism
Collaborative Initiative. Arthritis Rheumatol (2010) 62:2569–81.
doi: 10.1002/art.27584
39. van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease
Activity Score Using 28 Joint Counts (DAS28) in the Management of
Rheumatoid Arthritis. Clin Exp Rheumatol (2016) 34:S40–4.
40. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed.
Hillsdale, N.J: Lawrence Erlbaum Associates, Publishers (1988).
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